Sharps Technology (NASDAQ:STSS – Get Free Report) is one of 234 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Sharps Technology to similar businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.
Valuation & Earnings
This table compares Sharps Technology and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Sharps Technology | N/A | -$9.84 million | -0.44 |
| Sharps Technology Competitors | $1.03 billion | $3.51 million | -4,694.91 |
Sharps Technology’s competitors have higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Sharps Technology has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Sharps Technology’s competitors have a beta of 0.94, meaning that their average share price is 6% less volatile than the S&P 500.
Profitability
This table compares Sharps Technology and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sharps Technology | N/A | -102.25% | -72.97% |
| Sharps Technology Competitors | -673.57% | -130.38% | -27.83% |
Institutional and Insider Ownership
17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 48.2% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 12.6% of Sharps Technology shares are held by insiders. Comparatively, 15.3% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Sharps Technology and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sharps Technology | 0 | 0 | 0 | 0 | N/A |
| Sharps Technology Competitors | 1705 | 4505 | 8676 | 236 | 2.49 |
As a group, “Surgical & medical instruments” companies have a potential upside of 25.20%. Given Sharps Technology’s competitors higher possible upside, analysts plainly believe Sharps Technology has less favorable growth aspects than its competitors.
Summary
Sharps Technology competitors beat Sharps Technology on 6 of the 9 factors compared.
Sharps Technology Company Profile
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Receive News & Ratings for Sharps Technology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sharps Technology and related companies with MarketBeat.com’s FREE daily email newsletter.
